

Press release

Stockholm September 30, 2021

Increased number of shares and votes in Bactiguard

The number of shares and votes in Bactiguard Holding AB has changed due to the recently completed directed share issue. Through the directed share issue, the number of class B shares and votes in Bactiguard has increased by 1,500,000.

As of today, the last trading day of the month, the total number of shares in Bactiguard amounts to 35,043,885, of which 4,000,000 class A shares and 31,043,885 class B shares, corresponding to a total of 71,043,885 votes.

For more information, please contact:

Gabriella Björknert Caracciolo, CFO and vice president, phone: +46 72 141 62 49

This is information that Bactiguard Holding AB (publ) is obliged to make public pursuant to the Swedish Financial Instruments Trading Act. The information was submitted for publication, through the agency of the CFO on 30 September 2021 at 08.00 CET.

About Bactiguard

Bactiguard is a Swedish medical device company with a mission to save lives. To achieve this mission, we develop and supply infection prevention solutions which reduce the risk of infections and the use of antibiotics. This way, we save significant costs for healthcare and the society at large.

The Bactiguard technology is based on a thin noble metal alloy coating that prevents bacterial adhesion and biofilm formation on medical devices. Bactiguard offers the technology through licence agreements and our BIP (Bactiguard Infection Protection) portfolio of products. Urinary catheters with Bactiguard's coating are market leaders in the USA and Japan through our licensing partner BD. Bactiguard's product portfolio also includes a non-alcoholic product line for wound care and disinfection. It effectively kills viruses, bacteria and fungi while being biocompatible, pH neutral and tissue friendly. The active ingredient hypochlorous acid is the same substance as the body's immune cells use in their defence against infectious organisms.

Bactiguard is in a strong expansion phase in the markets in Europe, China, India, the Middle East and Southeast Asia through our own product portfolio and by establishing licensing deals in new therapy areas. Bactiguard has about 210 employees around the world. Its headquarters and one of three production facilities are located in Stockholm, the other two in Malaysia. Bactiguard is listed on Nasdaq Stockholm.

Read more about Bactiguard www.bactiguard.com

